Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine (NCT07159750)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Who can join: Review the eligibility criteria below.
Location: University of Miami, Miller School of Medicine — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- University of Miami, Miller School of Medicine — Miami, Florida
- FLENI — Buenos Aires,
- Pontificia Universidad Católica de Chile — Santiago,
- Neuromedica — Medellín,
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno — Rovinj,
- Charité Universitätsmedizin Berlin — Berlin,
- LMU University Hospital — München,
- University of L'Aquila — L’Aquila,
- University of Modena and Reggio Emilia — Modena,
- National Neurological Institute C. Mondino Foundation — Pavia,
- IRCCS San Raffaele — Roma,
- Universiti Putra Malaysia — Serdang, Selangor
- Neuroclinic Norway — Lillestrøm,
- Wrocław Medical University — Wroclaw,
- Hospital Santa Maria Lisbon — Lisbon,
- Germans Trias i Pujol Hospital — Badalona, Barcelona
- Vall d'Hebron University Hospital — Barcelona, Barcelona
- Hospital Universitari de Bellvitge — L'Hospitalet de Llobregat, Barcelona
- Fundació Sanitària Mollet — Mollet del Vallès, Barcelona
- Hospital de Viladecans — Viladecans, Barcelona
- Hospital General Universitario de Albacete — Albacete,
- Fundación Jiménez Díaz — Madrid,
- Hospital Universitario Gregorio Marañón — Madrid,
- La Paz University Hospital — Madrid,
- Hospital Clínico Universitario Lozano Blesa — Zaragoza,
📞 Contact the Study Coordinator
Phone: (+34) 93 489 30 00
Email: cefalea@vhir.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Migraine
- A Study of Wearable Devices to Predict Migraines — Rochester, Minnesota
- Treatment for Migraine and Mood — The Bronx, New York
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Birmingham, Alabama
- A Study to Evaluate White Matter Hyperintensities in Migraine — Phoenix, Arizona
- Migraine Manager (R01) — Cincinnati, Ohio
- Nerivio Efficacy Under High-Frequency Use — Bridgewater, New Jersey
Explore by condition: All Migraine clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.